NextCell Pharma AB (STO:NXTCL)
Sweden · Delayed Price · Currency is SEK 1.138
-0.034 (-2.90%)
May 21, 2026, 12:39 PM CET
NextCell Pharma AB Company Description
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden.
The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases.
It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.
NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.
NextCell Pharma AB
| Country | Sweden |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Mathias Svahn |
Contact Details
Address: Karolinska Institutet Science Park Huddinge, Stockholm County Stockholm County Sweden | |
| Phone | 46 87 35 55 95 |
Stock Details
| Ticker Symbol | NXTCL |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0009723125 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sofie Falk Jansson | Chief Executive Officer of Cellaviva |
| Lindsay Davies | Chief Scientific Officer and Chief Executive Officer of QVance |
| Dr. Mathias Svahn Ph.D. | Founder and Chief Executive Officer |
| Eric Gustafsson | Chief Financial Officer |
| Edvard Smith | Chief Medical Officer and Director |
| Sofia Sisay | Head of Clinical Trials |